REFERENCES
- Adams R J, Kutlar A, McKie V, Carl E, Nichols F T, Liu J C, McKie K, Clary A. 1994. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol. 45: 279–282. [PUBMED], [INFOTRIEVE]
- Adams R J, McKie V C, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols F T, Bonds D R, Brambilla D, Woods G, Olivieri N, Driscoll C, Miller S, Wang W, Hurlett A, Scher C, Berman B, Carl E, Jones A M, Roach E S, Wright E. 1998. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 339: 5–11. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Adams R J, Nichols F T, McKie V, McKie K, Milner P, Gammal T E. 1988. Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology. 38: 1012–1017. [PUBMED], [INFOTRIEVE]
- Alkjaersig N, Fletcher A, Joist H, Chaplin H, Jr.. 1976. Hemostatic alterations accompanying sickle cell pain crises. J Lab Clin Med. 88: 440–449. [PUBMED], [INFOTRIEVE]
- Arena J M. 1939. Cerebral vascular lesions accompanying sickle-cell anemia. J Pediatr. 14: 745–751
- Armstrong F D, Thompson R J, Jr., Wang W, Zimmerman R, Pegelow C H, Miller S, Moser F, Bello J, Hurtig A, Vass K. 1996. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 97: 864–870. [PUBMED], [INFOTRIEVE]
- Aslan M, Ryan T M, Adler B, Townes T M, Parks D A, Thompson J A, Tousson A, Gladwin M T, Patel R P, Tarpey M M, Batinic-Haberle I, White C R, Freeman B A. 2001. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 98: 15215–15220. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Balasa V V, Gruppo R A, Gartside P S, Kalinyak K A. 1999. Correlation of the C677T MTHFR genotype with homocysteine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 21: 397–400. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Balkaran B, Char G, Morris J S, Thomas P W, Serjeant B E, Serjeant G R. 1992. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 120: 360–366. [PUBMED], [INFOTRIEVE]
- Beurling-Harbury C, Schade S G. 1989. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol. 31: 237–241. [PUBMED], [INFOTRIEVE]
- Bridgers W H. 1939. Cerebral vascular disease accompanying sickle cell anemia. Am J Pathol. 15: 353–361
- Browne P V, Mosher D F, Steinberg M H, Hebbel R P. 1996. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol. 51: 296–301. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Buchanan G R, Holtkamp C A. 1983. Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol. 54: 595–603. [PUBMED], [INFOTRIEVE]
- Carvalho K S, Garg B P. 2002. Arterial strokes in children. Neurol Clin. 20: 1079–1100. [PUBMED], [INFOTRIEVE]
- Chaplin H J, Alkjaersig N, Fletcher A P, Michael J M, Joist J H. 1980. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost. 43: 218–221. [PUBMED], [INFOTRIEVE]
- Chaplin H J, Monroe M C, Malecek A C, Morgan L K, Michael J, Murphy W A. 1989. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 66: 574–584. [PUBMED], [INFOTRIEVE]
- Craft S, Schatz J, Glauser T A, Lee B, De, Baun M R. 1993. Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr. 123: 712–717. [PUBMED], [INFOTRIEVE]
- Cumming A M, Olujohungbe A, Keeney S, Singh H, Hay C R, Serjeant G R. 1999. The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol. 107: 569–571. [PUBMED], [INFOTRIEVE]
- del, Zoppo G, Ginis I, Hallenbeck J M, Iadecola C, Wang X, Feuerstein G Z. 2000. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10: 95–112. [PUBMED], [INFOTRIEVE]
- De, Veber G. 2002. Stroke and the child's brain: an overview of epidemiology, syndromes and risk factors. Curr Opin Neurol. 15: 133–138. [CROSSREF]
- Dobson S R, Holden K R, Nietert P J, Cure J K, Laver J H, Disco D, Abboud M R. 2002. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 99: 3144–3150. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Driscoll M C, Hurlet A, Styles L, MoVie V, Files B, Olivieri N, Pegelow C, Berman B, Drachtman R, Patel K, Brambilla D. 2003. Stroke risk in siblings with sickle cell anemia. Blood. 101: 2401–2404. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Du L M, Holzman S L, Mohandas N, Scott J P, Trost B A, Hillery C A. 2000. Increased fibrin deposition at sites of vasoocclusion in transgenic sickle mice. Blood. 96: 16, (Abstr).
- Fabry M E, Sengupta A, Suzuka S M, Costantini F, Rubin E M, Hofrichter J, Christoph G W, Manci E, Culberson D, Factor S M, et al, 1995. A second generation transgenic mouse model expressing both hemoglobin S (HbS). and HbS-Antilles results in increased phenotypic severity. Blood. 86: 2419–2428. [PUBMED], [INFOTRIEVE]
- Fabry M E, Suzuka S M, Weinberg R S, Lawrence C, Factor S M, Gilman J G, Costantini F, Nagel R L. 2001. Second generation knockout sickle mice: the effect of HbF. Blood. 97: 410–418. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Faraci F M, Brian J E, Jr.. 1994. Nitric oxide and the cerebral circulation. Stroke. 25: 692–703. [PUBMED], [INFOTRIEVE]
- Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse M F, Feremans W, Hunninck K, Toppet M, Philippet P, Van, Geet C, Sariban E. 2001. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 97: 3628–3632. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Francis R B, Jr.. 1988. Protein S deficiency in sickle cell anemia. J Lab Clin Med. 111: 571–576. [PUBMED], [INFOTRIEVE]
- Francis R B, Jr.. 1989. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 19: 105–111. [PUBMED], [INFOTRIEVE]
- Francis R B, Jr.. 1991. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis. 2: 341–353. [PUBMED], [INFOTRIEVE]
- Francis R B, Jr.. 1991. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis. 2: 341–353. [PUBMED], [INFOTRIEVE]
- Franck P FH, Bevers E M, Lubin B H, Comfurius P, Chiu D T, Op den, Kamp J A, Zwaal R FA, van, Deenen L L, Roelofsen B. 1985. Uncoupling of the membrane skeleton from the lipid bilayer: the cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickle cells. J Clin Invest. 75: 183–190. [PUBMED], [INFOTRIEVE]
- French J A, II, Kenny D, Scott J P, Hoffmann R G, Wood J D, Hudetz A G, Hillery C A. 1997. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood. 89: 4591–4599. [PUBMED], [INFOTRIEVE]
- Garber D W, Datta G, Chaddha M, Palgunachari M N, Hama S Y, Navab M, Fogelman A M, Segrest J P, Anantharamaiah G M. 2001. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 42: 545–552. [PUBMED], [INFOTRIEVE]
- Gee B E, Platt O S. 1995. Sickle reticulocytes adhere to VCAM-1. Blood. 85: 268–274. [PUBMED], [INFOTRIEVE]
- Gerald B, Sebes J I, Langston J W. 1980. Cerebral infarction secondary to sickle cell disease: arteriographic findings. AJR Am J Roentgenol. 134: 1209–1212. [PUBMED], [INFOTRIEVE]
- Glauser T A, Siegel M J, Lee B C, De, Baun M R. 1995. Accuracy of neurologic examination and history in detecting evidence of MRI-diagnosed cerebral infarctions in children with sickle cell hemoglobinopathy. J Child Neurol. 10: 88–92. [PUBMED], [INFOTRIEVE]
- Grabowski E F. 2002. Congenital and aquired prothrombotic risk factors in stroke. Curr Opin Neurol. 15: 139–144. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Granfortuna J, Zamkoff K, Urrutia E. 1986. Acute renal infarction in sickle cell disease. Am J Hematol. 23: 59–64. [PUBMED], [INFOTRIEVE]
- Green D, Scott J P. 1986. Is sickle cell crisis a thrombotic event?. Am J Hematol. 23: 317–321. [PUBMED], [INFOTRIEVE]
- Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. 1983. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr. 102: 781–784. [PUBMED], [INFOTRIEVE]
- Hillery C A, Du M C, Montgomery R R, Scott J P. 1996. Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood. 87: 4879–4886. [PUBMED], [INFOTRIEVE]
- Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L. 2003. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood. 101: 2865–2869. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Houston P E, Rana S, Sekhsaria S, Perlin E, Kim K S, Castro O L. 1997. Homocysteine in sickle cell disease: relationship to stroke. Am J Med. 103: 192–196. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Huang Z, Huang P L, Ma J, Meng W, Ayata C, Fishman M C, Moskowitz M A. 1996. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 16: 981–987. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Iadecola C, Pelligrino D A, Moskowitz M A, Lassen N A. 1994. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab. 14: 175–192. [PUBMED], [INFOTRIEVE]
- Iannone R, Casella J F, Fuch E J, et al, 2003. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 9: 519–528. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Inoue T K, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. 1997. Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease. Clin Neurol Neurosurg. 99(Suppl 2)S234–S237. [PUBMED], [INFOTRIEVE]
- Kahn M J, Scher C, Rozans M, Michaels R K, Leissinger C, Krause J. 1997. Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hematol. 54: 12–15. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Kaul D K, Hebbel R P. 2000. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 106: 411–420. [PUBMED], [INFOTRIEVE]
- Kaul D K, Liu X D, Fabry M E, Nagel R L. 2000. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 278: H1799–H1806. [PUBMED], [INFOTRIEVE]
- Kinney T R, Sleeper L A, Wang W C, Zimmerman R A, Pegelow C H, Ohene-Frempong K, Wethers D L, Bello J A, Vichinsky E P, Moser F G, Gallagher D M, De, Baun M R, Platt O S, Miller S T. 1999. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 103: 640–645. [PUBMED], [INFOTRIEVE]
- Koshy M, Thomas C, Goodwin J. 1990. Vascular lesions in the central nervous system in sickle cell disease. J Assoc Acad Minor Phys. 1: 71–78. [PUBMED], [INFOTRIEVE]
- Kurantsin-Mills J, Ibe B O, Natta C L, Raj J U, Siegel R S, Lessin L S. 1994. Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation. Br J Haematol. 87: 580–585. [PUBMED], [INFOTRIEVE]
- Kurantsin-Mills J, Ofosu F A, Safa T K, Siegel R S, Lessin L S. 1992. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol. 81: 539–544. [PUBMED], [INFOTRIEVE]
- Kuypers F A, Lewis R A, Hua M, Schott M A, Discher D, Ernest J D, Lubin B H. 1996. Detection of altered membrane phospholopid assymmetry in subpopulations of human red blood cells using flourescently labeled Annexin V. Blood. 87: 1179–1187. [PUBMED], [INFOTRIEVE]
- Lynch G F, Gorelick P B. 2000. Stroke in African Americans. Neurol Clin. 18: 273–290. [PUBMED], [INFOTRIEVE]
- Matsui N M, Borsig L, Rosen S D, Yaghmai M, Varki A, Embury S H. 2000. The novel adhesion of erythrocytes to P-selectin in sickle cell disease. Blood. 96: 600a, (Abstr).
- Miller S T, Macklin E A, Pegelow C H, Kinney T R, Sleeper L A, Bello J A, De, Witt L D, Gallagher D M, Guarini L, Moser F G, Ohene-Frempong K, Sanchez N, Vichinsky E P, Wang W C, Wethers D L, Younkin D P, Zimmerman R A, De, Baun M R. 2001. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 139: 385–390. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Miller S T, Sleeper L A, Pegelow C H, Enos L E, Wang W C, Weiner S J, Wethers D L, Smith J, Kinney T R. 2000. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 342: 83–89. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Moser F G, Miller S T, Bello J A, Pegelow C H, Zimmerman R A, Wang W C, Ohene-Frempong K, Schwartz A, Vichinsky E P, Gallagher D, Kinney T R. 1996. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol. 17: 965–972. [PUBMED], [INFOTRIEVE]
- Nagel R L, Fabry M E. 2001. The panoply of animal models for sickle cell anaemia. Br J Haematol. 112: 19–25. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Natarajan M, Udden M M, McIntire L V. 1996. Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood. 87: 4845–4852. [PUBMED], [INFOTRIEVE]
- Nath K A, Shah V, Haggard J J, Croatt A J, Smith L A, Hebbel R P, Katusic Z S. 2000. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 279: R1949–R1955. [PUBMED], [INFOTRIEVE]
- Navab M, Hama S Y, Ready S T, Ng C J, Van, Lenten B J, Laks H, Fogelman A M. 2002. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol. 13: 363–372. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ohene-Frempong K, Weiner S J, Sleeper L A, Miller S T, Embury S, Moohr J W, Wethers D L, Pegelow C H, Gill F M. 1998. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 91: 288–294. [PUBMED], [INFOTRIEVE]
- Osarogiagbon U R, Choong S, Belcher J D, Vercellotti G M, Paller M S, Hebbel R P. 2000. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 96: 314–320. [PUBMED], [INFOTRIEVE]
- Ou J, Ou Z, Jones D W, Holtzhauer S, Hatoum O A, Ackerman A W, Weihrauch D W, Gutterman D D, Guice K, Oldham K T, Hillery C A, Pritchard K A. 2003. L-4F, an apo A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 107: 2337–2341. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Pàszty C, Brion C M, Manci E, Witkowska H E, Stevens M E, Mohandas N, Rubin E M. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 278: 876–878. [CROSSREF]
- Pegelow C H, Adams R J, McKie V, Abboud M, Berman B, Miller S T, Olivieri N, Vichinsky E, Wang W, Brambilla D. 1995. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 126: 896–899. [PUBMED], [INFOTRIEVE]
- Pegelow C H, Macklin E A, Moser F G, Wang W C, Bello J A, Miller S T, Vichinsky E P, De, Baun M R, Guarini L, Zimmerman R A, Younkin D P, Gallagher D M, Kinney T R. 2002. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 99: 3014–3018. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Peters M, Plaat B E, ten, Cate H, Wolters H J, Weening R S, Brandjes D P. 1994. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost. 71: 169–172. [PUBMED], [INFOTRIEVE]
- Platt O S, Brambilla D J, Rosse W F, Milner P F, Castro O, Steinberg M H, Klug P P. 1994. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 330: 1639–1644. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Powars D, Wilson B, Imbus C, Pagalow C, Allen J. 1978. The natural history of stroke in sickle cell anemia. Am J Med. 65: 461–471. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Powars D R. 1991. Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol. 28: 202–208. [PUBMED], [INFOTRIEVE]
- Prengler M, Pavlakis S G, Prohovnik I, Adams R J. 2002. Sickle cell disease: the neurological complications. Ann Neurol. 51: 543–552. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Punzalan R C, Holzman S L, Trost B A, Pàszty C, Mohandas N, Scott J P, Hillery C A. 1999. Spontaneous stroke and increased erythrocyte adhesion in transgenic knockout sickle cell mice. Blood. 94: 419a, (Abstr).
- Punzalan R C, Trost B A, Scott J P, Hudetz A G, Hillery C A. 1998. Chondroitin sulfate-A limits cerebral ischemia induced by nitric oxide inhibition in sickle erythrocyte-infused rats. Blood. 92: 329a, (Abstr).
- Rothman S M, Fulling K H, Nelson J S. 1986. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol. 20: 684–690. [PUBMED], [INFOTRIEVE]
- Russell M O, Goldberg H I, Hodson A, Kim H C, Halus J, Reivich M, Schwartz E. 1984. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 63: 162–169. [PUBMED], [INFOTRIEVE]
- Ryan T M, Ciavatta D J, Townes T M. 1997. Knockout-transgenic mouse model of sickle cell disease. Science. 278: 873–876. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Salvaggio J E, Arnold C A, Banov C H. 1963. Long-term anticoagulation in sickle cell disease. N Engl J Med. 269: 182–186. [PUBMED], [INFOTRIEVE]
- Sarnaik S A, Ballas S K. 2001. Molecular characteristics of pediatric patients with sickle cell anemia and stroke. Am J Hematol. 67: 179–182. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Schatz J, Brown R T, Pascual J M, Hsu L, De, Baun M R. 2001. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 56: 1109–1111. [PUBMED], [INFOTRIEVE]
- Schnog J B, Kater A P, Mac, Gillavry M R, Duits A J, Lard L R, Der, Dijs F P, Brandjes D P, ten, Cate H, van, Eps L W, Rojer R A. 2001. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol. 68: 179–183. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Schnog J B, Mac, Gillavry M R, Rojer R A, Meijers J C, Fijnheer R, ten, Cate H, Brandjes D P, Duits A J. 2002. No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. Am J Hematol. 71: 53–55. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Scothorn D J, Price C, Schwartz D, Terrill C, Buchanan G R, Shurney W, Sarniak I, Fallon R, Chu J Y, Pegelow C H, Wang W, Casella J F, Resar L S, Berman B, Adamkiewicz T, Hsu L L, Ohene-Frempong K, Smith-Whitley K, Mahoney D, Scott J P, Woods G M, Watanabe M, De, Baun M R. 2002. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 140: 348–354. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Semple M J, Al-Hasani S F, Kioy P, Savidge G F. 1984. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost. 51: 303–306. [PUBMED], [INFOTRIEVE]
- Setty B N, Chen D, Stuart M J. 1995. Sickle cell vasoocclusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids. Pediatr Res. 38: 95–102. [PUBMED], [INFOTRIEVE]
- Setty B N, Kulkarni S, Rao A K, Stuart M J. 2000. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 96: 1119–1124. [PUBMED], [INFOTRIEVE]
- Solovey A, Gui L, Key N S, Hebbel R P. 1998. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 101: 1899–1904. [PUBMED], [INFOTRIEVE]
- Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel R P. 1997. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 337: 1584–1590. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Steen R G, Helton K J, Horwitz E M, Benaim E, Thompson S, Bowman L C, Krance R, Wang W C, Cunningham J M. 2001. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol. 49: 222–229. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Stockman J A, Nigro M A, Mishkin M M, Oski F A. 1972. Occlusion of large cerebral vessels in sickle cell anemia. N Engl J Med. 287: 847–849
- Stuart J, Stone P C, Akinola N O, Gallimore J R, Pepys M B. 1994. Monitoring the acute phase response to vasoocclusive crisis in sickle cell disease. J Clin Pathol. 47: 166–169. [PUBMED], [INFOTRIEVE]
- Stuart M J, Setty B N. 1999. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood. 94: 1555–1560. [PUBMED], [INFOTRIEVE]
- Stuart M J, Stockman J A, Oski F A. 1974. Abnormalities of platelet aggregation in the vasoocclusive crisis of sickle-cell anemia. J Pediatr. 85: 629–632. [PUBMED], [INFOTRIEVE]
- Sumoza A, de, Bisotti R, Sumoza D, Fairbanks V. 2002. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol. 71: 161–165. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Swerlick R A, Eckman J R, Kumar A, Jeitler M, Wick T M. 1993. a4b1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood. 82: 1891–1899. [PUBMED], [INFOTRIEVE]
- Sydenstricker V P, Mulherin W A, Houseal R W. 1923. Sickle cell anemia: report of two cases in children, with necropsy in one case. Am J Dis Child. 26: 132–154
- Tagami M, Ikeda K, Nara Y, Fujino H, Kubota A, Numano F, Yamori Y. 1995. Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor. Lab Invest. 72: 174–182. [PUBMED], [INFOTRIEVE]
- Tam D A. 1997. Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol. 12: 19–21. [PUBMED], [INFOTRIEVE]
- Tang D C, Prauner R, Liu W L, Kim K H, Hirsch R P, Driscoll M C, Rodgers G P. 2001. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol. 68: 164–169. [PUBMED], [INFOTRIEVE]
- Taylor J G, Tang D C, Savage S A, Leitman S F, Heller S I, Serjeant G R, Rodgers G P, Chanock S J. 2002. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood. 100: 4303–4309. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Tuohy A M, McKie V, Manci E A, Adams R J. 1997. Internal carotid artery occlusion in a child with sickle cell disease: case report and immunohistochemical study. J Pediatr Hematol Oncol. 19: 455–458. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Vichinsky E P, Lubin B H. 1994. A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 83: 1124–1128. [PUBMED], [INFOTRIEVE]
- Walters M C, Storb R, Patience M, Leisenring W, Taylor T, Sanders J E, Buchanan G E, Rogers Z R, Dinndorf P, Davies S C, Roberts I A, Dickerhoff R, Yeager A M, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong W Y, Scott J P, Margolis D, Vichinsky E, Wall D A, Wayne A S, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer W C, Smith F O, Sullivan K M. 2000. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 95: 1918–1924. [PUBMED], [INFOTRIEVE]
- Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Zimmerman R, Armstrong F D. 2001. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 139: 391–397. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Wang W C, Kovnar E H, Tonkin I L, Mulhern R K, Langston J W, Day S W, Schell M J, Wilimas J A. 1991. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 118: 377–382. [PUBMED], [INFOTRIEVE]
- Ware R E, Zimmerman S A, Schultz W H. 1999. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 94: 3022–3026. [PUBMED], [INFOTRIEVE]
- Westwick J, Watson-Williams E J, Krishnamurthi S, Marks G, Ellis V, Scully M F, White J M, Kakkar V V. 1983. Platelet activation during steady state sickle cell disease. J Med. 14: 17–36. [PUBMED], [INFOTRIEVE]
- Wolters H J, ten, Cate H, Thomas L L, Brandjes D P, van der, Ende A, van der, Heiden Y, Statius vEL. 1995. Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?. Br J Haematol. 90: 715–717. [PUBMED], [INFOTRIEVE]
- Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. 1997. Platelet activation and platelet–erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 129: 507–516. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M. 2000. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 31: 930–935. [PUBMED], [INFOTRIEVE]
- Zago M A, Costa F F, Ismael S J, Tone L G, Bottura C. 1984. Treatment of sickle cell diseases with aspirin. Acta Haematol. 72: 61–64. [PUBMED], [INFOTRIEVE]
- Zimmerman S A, Ware R E. 1998. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol. 59: 267–272. [CROSSREF], [PUBMED], [INFOTRIEVE]